

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Bempedoic acid for treating primary hypercholesterolaemia or mixed dyslipidemia [ID1515]

Final stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Daiichi Sankyo UK (bempedoic acid) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Black Health Agency • Cardiovascular Care Partnership • Circulation Foundation • HEART UK • Muslim Council of Britain • Network of Sikh Organisations • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British Association for Nursing in Cardiovascular Care • British Cardiovascular Intervention Society • British Cardiovascular Society • British Dietetic Association • British Geriatrics Society • British Heart Foundation • British Inherited Metabolic Disease Group • British Nuclear Cardiology Society • British Society for Genetic Medicine • British Society of Cardiovascular Imaging • Primary Care Cardiovascular Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Accord Healthcare (atorvastatin, ezetimibe, fluvastatin, pravastatin, rosuvastatin, simvastatin) • ADVANZ Pharma (ezetimibe) • Amgen (evolocumab) • AstraZeneca (rosuvastatin) • Aurobindo Pharma – Milpharm (atorvastatin, ezetimibe, pravastatin, rosuvastatin, simvastatin) • Consilient Health (atorvastatin) • Dexcel Pharma (atorvastatin) • Lupin Healthcare (simvastatin) • Merck Sharp & Dohme (ezetimibe,

Final stakeholder list for the proposed Technology Appraisal of bempedoic acid for treating primary hypercholesterolaemia or mixed dyslipidemia ID1515

Issue date: September 2019

© National Institute for Health and Care Excellence 2019. All rights reserved.

Appendix C

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Society for Cardiological Science & Technology • Society for Endocrinology • Society for Vascular Technology • Society of Vascular Nurses • UK Clinical Pharmacy Association • UK Health Forum • Vascular Society of Great Britain & Ireland <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • NHS Lancashire North CCG • NHS Wandsworth CCG • Welsh Government 	<ul style="list-style-type: none"> simvastatin) • Mylan (atorvastatin, ezetimibe, fluvastatin, pravastatin, rosuvastatin, simvastatin) • Novartis Pharmaceuticals (fluvastatin) • Pfizer (atorvastatin) • Rosemont Pharmaceuticals (simvastatin) • Sandoz (ezetimibe, fluvastatin, rosuvastatin, simvastatin) • Sanofi (alirocumab) • Sun Pharmaceuticals (atorvastatin, rosuvastatin) • Wockhardt UK (atorvastatin) • Zentiva (atorvastatin, ezetimibe, rosuvastatin, simvastatin) • <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Society for Cardiovascular Research • Central Cardiac Audit Database • Cochrane Heart Group • Cochrane Metabolic & Endocrine Disorders Group • Genomics England • Heart Research UK • MRC Clinical Trials Unit • National Institute for Cardiovascular Preventions and Outcomes • National Institute for Health Research • Wellcome Trust <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do share it. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.